braf mutation predicts sensitivity mek inhibition 
kinase pathway comprising ras raf mitogen-activated protein kinase kinase mek extracellular signal regulated kinase erk activated human tumours often gain-of-function mutations ras raf family members using small-molecule inhibitors mek integrated genetic pharmacologic analysis find mutation braf associated enhanced selective sensitivity mek inhibition compared either wild-type cells cells harbouring ras mutation mek dependency observed braf mutant cells regardless tissue lineage correlated downregulation cyclin d1 protein expression induction g1 arrest pharmacological mek inhibition completely abrogated tumour growth braf mutant xenografts whereas ras mutant tumours partially inhibited data suggest exquisite dependency mek activity braf mutant tumours offer rational therapeutic strategy genetically defined tumour subtype 
